COMPOUNDS AND USES THEREOF - 150
    1.
    发明申请
    COMPOUNDS AND USES THEREOF - 150 审中-公开
    化合物及其用途 - 150

    公开(公告)号:US20100016283A1

    公开(公告)日:2010-01-21

    申请号:US12520152

    申请日:2007-12-19

    CPC分类号: C07D281/16

    摘要: Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.

    摘要翻译: 下式(I)及其药学上可接受的盐或互变异构体,其组合物和使用方法。 这些新型化合物提供治疗或预防与精神分裂症和其他精神病,痴呆和其他认知障碍,焦虑障碍,情绪障碍,睡眠障碍,通常在婴儿期,儿童期或青春期首先诊断的疾病有关的至少一种症状或病症,以及 神经变性疾病

    COMPOUNDS AND USES THEREOF - 152
    2.
    发明申请
    COMPOUNDS AND USES THEREOF - 152 审中-公开
    化合物及其用途 - 152

    公开(公告)号:US20100056492A1

    公开(公告)日:2010-03-04

    申请号:US12520167

    申请日:2007-12-19

    IPC分类号: A61K31/554 C07D417/04

    CPC分类号: C07D281/16

    摘要: This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.

    摘要翻译: 本发明涉及具有以下结构式(I)的新化合物及其药学上可接受的盐或互变异构体,其组合物和使用方法。 这些新化合物提供治疗或预防与精神分裂症和其他精神病,痴呆和其他认知障碍,焦虑障碍,情绪障碍,睡眠障碍,通常在婴儿期,儿童期或青春期中首先诊断的疾病相关的至少一种症状或病症,以及 神经变性疾病

    COMPOUNDS AND USES THEREOF - 151
    3.
    发明申请
    COMPOUNDS AND USES THEREOF - 151 审中-公开
    化合物及其用途 - 151

    公开(公告)号:US20100016284A1

    公开(公告)日:2010-01-21

    申请号:US12520162

    申请日:2007-12-19

    CPC分类号: C07D417/04

    摘要: This invention relates to novel compounds having the structural Formula I below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.

    摘要翻译: 本发明涉及具有以下结构式I的新化合物及其药学上可接受的盐或互变异构体,其组合物和使用方法。 这些新化合物提供治疗或预防与精神分裂症和其他精神病,痴呆和其他认知障碍,焦虑障碍,情绪障碍,睡眠障碍,通常在婴儿期,儿童期或青春期中首先诊断的疾病相关的至少一种症状或病症,以及 神经变性疾病

    COMPOUNDS AND USES THEREOF - 177
    5.
    发明申请
    COMPOUNDS AND USES THEREOF - 177 审中-公开
    化合物及其用途 - 177

    公开(公告)号:US20100093699A1

    公开(公告)日:2010-04-15

    申请号:US12520133

    申请日:2007-12-19

    CPC分类号: C07D281/16

    摘要: This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence, and neurodegenerative disorders.

    摘要翻译: 本发明涉及具有以下结构式(I)的新化合物及其药学上可接受的盐,组合物和使用方法。 这些新化合物提供治疗或预防与精神分裂症和其他精神病,痴呆和其他认知障碍,焦虑障碍,情绪障碍,睡眠障碍,通常在婴儿期,儿童期或青少年中首先诊断的疾病有关的至少一种症状或病症, 和神经变性疾病。

    Therapeutic benzoxazole compounds
    8.
    发明授权
    Therapeutic benzoxazole compounds 失效
    治疗性苯并恶唑化合物

    公开(公告)号:US07045539B2

    公开(公告)日:2006-05-16

    申请号:US10450927

    申请日:2001-12-19

    摘要: Compounds of the formula (I) for use as an estrogen receptor-β-selective ligand are described wherein: X is O or S; and R1, R3 R6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.

    摘要翻译: 描述了用作雌激素受体-β-选择性配体的式(I)化合物,其中:X为O或S; 和R 1,R 3,R 6和S 6如说明书中所述。 描述了这些化合物在治疗阿尔茨海默病,焦虑障碍,抑郁障碍,骨质疏松症,心血管疾病,类风湿性关节炎和前列腺癌中的用途。 制作它们的过程也是如此。

    Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors
    10.
    发明申请
    Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors 审中-公开
    酰基甘氨酰胺衍生物及其作为Nk1拮抗剂和5-羟色胺再摄取抑制剂的用途

    公开(公告)号:US20070203139A1

    公开(公告)日:2007-08-30

    申请号:US10599823

    申请日:2005-04-06

    摘要: Compounds of the following Formula (I) wherein R1 and R2 are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar1 is (substituted) phenyl and Ar1 is (substituted) phenyl, naphthyl or tetralin, further as defined in the specification, in vivo-hydrolysable precursors and pharmaceutically acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. The compounds are neurokinin 1 (NK1) receptor antagonists and/or serotonin reuptake inhibitors, with medical indications for depression, anxiety disorders and other conditions.

    摘要翻译: 其中R 1和R 2的下式(I)的化合物与它们所结合的N一起独立地选自烷基或烯基或杂环, n是0-2,Ar 1是(取代的)苯基,Ar 1是(取代的)苯基,萘基或四氢化萘,进一步如说明书中所定义, 可水解前体及其药学上可接受的盐,治疗用途及药物组合物及使用其的治疗方法。 这些化合物是神经激肽1(NK 1)受体拮抗剂和/或5-羟色胺再摄取抑制剂,具有抑郁症,焦虑障碍和其他病症的医学适应症。